Manager TitleAgeSince
Chief Executive Officer 64 30/03/2022
Director of Finance/CFO - 31/07/2024
Director TitleAgeSince
Chairman 70 19/11/2019
Director/Board Member 65 31/05/2013
Director/Board Member 80 29/12/2021
Date Insider Type Main position Quantity % Market Cap.
22/06/22 Free 111,193 0.2314%
19/01/21 Sell 1 0.0000%
19/01/21 Sell 2,000 0.0179%
Change 5-day change 1-year change 3-year change Capi.($)
-75.00%-.--% - - 817K
-1.67%-4.78%+37.02%-4.42% 80.65B
-0.90%+0.65%-20.11%-34.58% 59.9B
-3.35%-4.92%+463.91%+21.22% 57B
-6.78%-5.59%-5.25%+27.67% 53.35B
-2.43%-0.64%+7.60%+165.06% 49.29B
-1.35%+0.79%+64.72%-17.56% 32.73B
-2.64%-2.69%+48.59%+91.84% 25.89B
-0.09%+6.23%+18.13%+218.05% 23.9B
-0.34%+1.04%+59.33%+110.57% 17.07B
Average -9.50%+1.57%+74.88%+64.21% 44.42B
Weighted average by Cap. -2.52%+1.01%+82.90%+43.26%
Logo Spexis AG
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
Employees
50
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. SPEX Stock